RevolutionLogo.png
Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
24 mai 2023 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
08 mai 2023 16h02 HE | Revolution Medicines, Inc.
First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) – progressing on plan Appointment of chief medical officer and key leaders across...
RevolutionLogo.png
Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023
01 mai 2023 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
RevolutionLogo.png
Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference
13 avr. 2023 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
06 avr. 2023 07h00 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
07 mars 2023 16h02 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Immuneering-logo (1).png
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
05 mars 2023 18h30 HE | Immuneering Corporation
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid...
RevolutionLogo.png
Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock
02 mars 2023 21h15 HE | Revolution Medicines, Inc.
REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines Announces Commencement of Public Offering of Common Stock
01 mars 2023 16h17 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
27 févr. 2023 16h05 HE | Revolution Medicines, Inc.
Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805...